First Tracks Biotherapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -0.6% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 14.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -40.9% | Better than 10% |
| Return on invested capital | -43.4% | Better than 7% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -3.4% | Better than 66% |
| 6-month return | 142.4% | Better than 100% |
| Distance below 52-week high | 24.0% | Better than 52% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 10.8x | Better than 94% |
| Debt to assets | 3.6% | Better than 83% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 81.1% | Better than 79% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 44.46
- Open
- 43.99
- Day range
- 41.23 - 44.74
- Avg price
- 42.18
- Volume
- 504.37K
- Turnover
- 21.27M
- Turnover ratei
- 1.92%
- Volume ratioi
- 0.94
- Amplitudei
- 7.90%
- 52-week rangei
- 14.72 - 54.78
Valuation
- P/Ei
- -8.46
- P/E (TTM)i
- -9.98
- P/Bi
- 11.59
- EPSi
- -4.92
- Book value / shi
- 3.59
- Net profit
- -206.85M
- Net assets
- 151.01M
Share structure
- Market cap
- 1.75B
- Float capi
- 1.10B
- Shares out
- 42.02M
- Float sharesi
- 26.33M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-04-06
24.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+1.35M net over the window
Short interest
- Shares short
- 5.06M
- % of floati
- 14.08%
- Days to coveri
- 6.52
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of First Tracks Biotherapeutics (TRAX)?
First Tracks Biotherapeutics last traded at 41.64. This page shows a periodic quote snapshot. Check the displayed quote time.
What is First Tracks Biotherapeutics's market cap?
About 1.75B.
What is the P/E ratio of First Tracks Biotherapeutics?
The trailing twelve-month P/E is -9.98. The Valuation tab shows it against the stock's own five-year range.
Does First Tracks Biotherapeutics pay a dividend?
First Tracks Biotherapeutics does not currently pay a regular dividend.
Is First Tracks Biotherapeutics a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 75.40, which implies 81.1% upside from the current price. This is not investment advice.
What is First Tracks Biotherapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates First Tracks Biotherapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
First Tracks Biotherapeutics discussion 0 comments